Her-2 Positive Breast Cancer Market in US 2015-2019

HER-2 Positive Breast Cancer Market in US 2015-2019

[email protected]

USA – CANADA – UK – CHINA – INDIA


The report discusses the following in-depth:

• Market Size and Forecast

• Market Segmentation

• Buying Criteria

• Vendor Landscape

• Business Segmentation

• Geographical Segmentation

For more information on theHER-2 Positive Breast Cancer

Market in US 2015-2019,please mail us at

[email protected]


Key Trends

TechNavio’s Senior Analyst says, “Despite the presence of several challenges, the market is expected to grow at a rapid pace during the forecast period because of some emerging trends. One such trend is the increase in awareness. Awareness and screening programs can help diagnose potential breast cancer cases, which might otherwise remain undetected till the last stage. ”

• HER-2 is a member of the human EGFR family. Overexpression or amplification of this oncogene has been linked to certain aggressive types of breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than other forms of cancers. They also tend to affect women more than men. The GLOBOCAN project reported that, in 2012, breast cancer accounted for 11.90 percent of the total cancer cases and led to 522,000 deaths worldwide.

• TechNavio's analysts forecast the HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65 percent over the period 2014-2019.

• Understanding the key drivers influencing the market

• Understanding the challenges faced by the market

• Activities of various stakeholders involved

• Key focus areas for the vendors

• Major trends that will shape the future of this market

• Vendor landscape and trajectory of the market

• Conclusion

Scope of The Report

A detailed analysis of each market driver, challenge

and trend isavailable in our report:



http://www.technavio.com/report/her-2-positive-breast-cancer-market-in-us-2015-2019?utm_source=Slideshare&utm_medium=PPT&utm_content=T1&utm_campaign=Report



Vendors

To understand the vendor landscape and for a full list of vendors view our report:


Celgene Corp.

F. Hoffmann-La Roche Ltd.

GlaxoSmithKline plc

Celgene offers the small molecule drug, Abraxane for the treatment of HER-2 positive breast cancer.

Roche, a subsidiary of Roche Holding AG, is a healthcare company that undertakes discovery, development, manufacturing, and marketing of innovative diagnostic and therapeutic products and services. The company is headquartered in Basel, Switzerland, and has many pharmaceutical and diagnostic sites worldwide.

GSK has a diversified portfolio of products and provides assistance in treating major diseases such as asthma, cancer, infections, mental health, diabetes, and digestive conditions, and in viral diseases. The Consumer Healthcare division also plays a vital role in the functioning of GSK.

http://www.technavio.com/report/automotive-led-lighting-market-in-americas-2015-2019?utm_source=Slideshare&utm_medium=PPT&utm_content=T1&utm_campaign=Report




Market Landscape

• The HER-2 Positive Breast Cancer market in the US is expected to grow at a rapid pace during the forecast period because of an increase in the prevalence of breast cancer and better awareness.

• Currently, breast cancer drugs have various undesirable side effects; therefore, the demand for safer drugs is increasing.

• The present market for HER-2 positive breast cancer prescription drugs is served by Celgene, F. Hoffmann-La Roche, GlaxoSmithKline, Novartis, and Sanofi.

• Some of the most effective targeted therapies for the treatment of HER-2 positive breast cancer are Perjeta, Kadcyla, and Herceptin.

• Herceptin is a gold standard therapy for the treatment of breast cancer in patients and has been in use since 1998.


Key Buying CriteriaGuest Bloggers

• Authenticity • Delivery • Price• Service

Support

Parameter Details

Affordability Drugs should be affordable for the patients

Availability Drugs should be readily available for the patients

Efficacy Drugs with higher efficacy will have a high demand

Safety Drugs with less side effects are expected to be high in demand

• Growth Forecasts?

• Market Analysis?

• Revenue Forecasts?

• Regional and Country level Analysis?

• Competitive Structure?

• Emerging Trends?

• Vendor Landscape?

• Other?

What Would You Like to Learn From TechNavio?


Let us identify your needs.We would love to hear more!




Our Report Covers: Market Scenarios, Vendor landscape & Industry Road Maps.

You have the Option to Customize Reports & Access Analysts on every Report Purchase.

Purchasing this report?

For media enquiries,please drop us a mail at

[email protected]

We’ll include an hour with our analysts to discuss the report findings.

For free.

mailto:[email protected]


Access the Report


India: An Overview


About Us


Thank You!

North America

Chicago, USA

Phone: +1 630 333 9501

Fax: +1 630 833 2171

Europe

London, United Kingdom

Phone: +44 208 123 1770

Fax: +44 845 280 2825

Asia

Bangalore, India

Phone: +91 934 254 0560

Fax: +91 80 4080 6070

DISCLAIMER

This presentation is intended solely for showcasing Infiniti’s research capabilities. All information contained within this presentation has been randomized and should not be used for any kind of analysis and/or for decision making purpose. All trademarks and copyrights remain the sole ownership of their rightful owners/licensees. In no event shall

Infiniti Research have any liability to any party for special, incidental, tort, or consequential damages arising out of or in connection with this report, even if Infiniti Research has been advised of the possibility of such damages.

Copyright ©2013 Infiniti Research Limited. All Rights Reserved.

Reproduction without written permission is completely forbidden.

NOT FOR FURTHER DISTRIBUTION

https://www.facebook.com/pages/TechNavio/541097752635345

https://twitter.com/TechNavio

https://www.linkedin.com/company/technavio

https://www.youtube.com/channel/UCy4jXQNIs1a_c9W9pYxZX3g